Loading...
•
Dec 31, 2021
Eton Q4 2021 Earnings Report
Eton reported a net income of $1.0 million and revenue of $6.1 million, driven by a $5.0 million milestone payment from Azurity Pharmaceuticals.
Key Takeaways
Eton Pharmaceuticals reported a profitable fourth quarter with a net income of $1.0 million, a significant improvement compared to the previous year's net loss. Revenue reached $6.1 million, boosted by a milestone payment. The company launched carglumic acid, saw accelerated growth of ALKINDI SPRINKLE through a co-promotion partnership, and launched Rezipres.
Eton launched carglumic acid in late December 2021, the first generic version of Carbaglu®.
A co-promotion agreement with Tolmar Pharmaceuticals accelerated the growth of ALKINDI SPRINKLE®.
Eton launched another new product, Rezipres.
The company has four additional products submitted to the FDA for approval.
Forward Guidance
Eton expects continued growth and new product approvals in the coming quarters.
Positive Outlook
- Carglumic acid launch tracking ahead of initial expectations.
- Co-promotion partnership with Tolmar accelerating growth of ALKINDI SPRINKLE®.
- Launch of another new product, Rezipres.
- Progress with four additional products submitted to the FDA.
- Plans to submit supplement applications for Biorphen and Rezipres vials to the FDA in the second quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...